ProSomnus Announces Third Quarter 2023 Investor Call and Business Update
Investor Call Dial-In Information
Interested parties may register for the conference call using the following link: ProSomnus Q3 2023 Conference Call. You may access the live webcast of the conference call by using the following link: ProSomnus Q3 2023 Webcast. The link will also be posted in the Investor Relations section of the ProSomnus website at News & Events.
ProSomnus (NASDAQ: OSA) is a leading CPAP alternative for the treatment of Obstructive Sleep Apnea, a serious medical disease affecting over 1 billion people worldwide, that is associated with comorbidities including heart failure, stroke, hypertension, morbid obesity, and type 2 diabetes. ProSomnus intraoral medical devices are engineered to precisely track the treatment plan and anatomy for each patient. Non-invasive, patient preferred and easy to use, ProSomnus devices have demonstrated excellent efficacy, safety, adherence, and overall outcomes in a growing body of clinical investigations. ProSomnus precision intraoral devices are FDA-cleared, patented, and covered by commercial medical insurance, Medicare, TRICARE and many Government sponsored healthcare plans around the world, representing over 200 million covered lives. To learn more, visit www.ProSomnus.com.
Source: ProSomnus Sleep Technologies, Inc.